| Brand Name | PANTOCID 20 |
| Generic / Medicine Name | PANTOPRAZOLE GASTRO RESISTANT TABLETS BP 20 MG |
| Strength | 20 mg |
| Pack Size | 50's |
| Package Type | Alu Alu |
| NMRA Approved price (MRP) |
LKR 1,587 / 50 caps
( LKR 31.74 / Each Tablet)
|
| Registration No | M013968 |
| Date of First Registration | 12.06.2024 |
| Registration Details with Validity | 12.06.2026 |
| Status | Valid |
| Import Licence No | IM013968 |
| Import Licence Validity | 12.06.2026 — Expiring Soon |
| Authorised person(pharmacist) | Ms. Krishani |
| SLMC Registration No | SLMC 10241 |
| NMRA Licence No | WP078412 |
| Validity | 26.05.2026 |
| Email ID | info@hemas.com |
| Phone Number | +94 112 478 925 |
| Mobile | +94 776 478 925 |
| Year of Establishment | 1948 |
| Number of Agencies registered | 100 |
| Total Products Registered | 1500 |
| Company Name | Life Connect (Pvt)Ltd - Colombo 08 |
| Importer Licence No | 124512 |
| NMRA Licence No | WP012345 |
| Validity | 26.05.2027 |
| Email ID | info@lifeconnect.lk |
| Phone Number | +94 112 444 555 |
| Address | D S, 39/2 Senanayake Dr, Colombo 8 Sri Lanka |
| Year of Establishment | 2015 |
| Number of Agencies registered | 02 |
| Products Imported | 246 |
| Contact Number | +91 8 8209 2666 |
| Email ID | info@sunpharma.com |
| CP Registration No | CP 0888 |
| CEO / Chairman | Mr. Dilip Shanghvi |
| Mobile Number | +91 8 8209 2666 |
| Total products registered | 123 |
| Phone No | +94 112 777 999 |
| Email ID | vasana@gmail.com |
| Pharmacist Name | Ms. Vindya |
| Pharmacist Mobile | +94 777 000 444 |
| SLMC ID | 2345 |
| NMRA Licence No | RL 05210 |
| Validity | 31.12.2025 |
| Owner Name | Mr. Ram |
| Owner Mobile | +94 777 987 654 |
These highlights do not include all the information needed to use PANTOPRAZOLE SODIUM FOR DELAYED-RELEASE ORAL SUSPENSION safely and effectively. See full prescribing information for PANTOPRAZOLE SODIUM FOR DELAYED-RELEASE ORAL SUSPENSION.
PANTOPRAZOLE SODIUM for delayed-release oral suspension
Pantoprazole sodium is a proton pump inhibitor (PPI) indicated for the following:
- Short-term treatment of erosive esophagitis associated with gastroesophageal reflux disease (GERD) (1.1)
- Maintenance of healing of erosive esophagitis (1.2)
- Pathological hypersecretory conditions including Zollinger-Ellison (ZE) syndrome (1.3)
- Patients with known hypersensitivity to any component of the formulation or to substituted benzimidazoles (4)
- Patients receiving rilpivirine-containing products (4, 7)
Experience in patients taking very high doses of pantoprazole (greater than 240 mg) is limited. Spontaneous postmarketing reports of overdose are generally within the known safety profile of pantoprazole.
Pantoprazole is not removed by hemodialysis. In case of overdosage, treatment should be symptomatic and supportive.
Single oral doses of pantoprazole at 709 mg/kg, 798 mg/kg, and 887 mg/kg were lethal to mice, rats, and dogs, respectively. The symptoms of acute toxicity were hypoactivity, ataxia, hunched sitting, limb-splay, lateral position, segregation, absence of ear reflex, and tremor.
If overexposure to pantoprazole occurs, call your Poison Control Center at 1-800-222-1222.
| Prescription Ref | Date Dispensed | Quantity | Invoice No. | Batch No. |
|---|---|---|---|---|
| Rx_1 | 15.03.2026 | 10 Tablets | 12466 | B 123123 |
| Rx_2 | 20.03.2026 | 20 Tablets | 12491 | B 23123 |
| Rx_3 | 31.03.2026 | 10 Tablets | 12516 | B 23123 |